Mood disorder in idiopathic pulmonary fibrosis: response to pulmonary rehabilitation

Background Pulmonary rehabilitation improves mood disorder in COPD, but there are limited data in idiopathic pulmonary fibrosis (IPF). The aims of this cohort study were to investigate whether pulmonary rehabilitation reduces mood disorder in IPF, and estimate the minimal important difference (MID) of the Hospital Anxiety and Depression Scale (HADS). Methods HADS and core pulmonary rehabilitation outcomes were measured in 166 participants before and after an 8-week, in-person, outpatient pulmonary rehabilitation programme. Anchor- and distribution-based methods were used to calculate the MID of HADS-Anxiety (A) and HADS-Depression (D). Results Suggestive or probable anxiety and depression (HADS ≥8) were present in 35% and 37% of participants, respectively, at baseline, and this reduced significantly following pulmonary rehabilitation (post-pulmonary rehabilitation: HADS-A 23%, HADS-D 26%). Overall, there was a significant reduction in HADS-D (mean change −1.1, 95% CI −1.6– −0.5), but not HADS-A (−0.6, −1.3–0.15) with pulmonary rehabilitation. Subgroup analysis of those with HADS ≥8 revealed significant improvements in HADS domains (mean change: HADS-A −4.5, 95% CI −5.7– −3.4; median change: HADS-D −4.0, interquartile range −6.0– −1.0). The mean (range) MID estimates for HADS-A and HADS-D were −2 (−2.3– −1.7) and −1.2 (−1.9– −0.5), respectively. Conclusion In people with IPF and suggestive or probable mood disorder, pulmonary rehabilitation reduces anxiety and depression. In people with idiopathic pulmonary fibrosis and suggestive or probable mood disorder, pulmonary rehabilitation reduces anxiety and depression. Mean MID estimates for HADS-Anxiety and HADS-Depression were −2 and −1.2, respectively. https://bit.ly/42SWFrf

[1]  R. Casaburi,et al.  The effectiveness of pulmonary rehabilitation on chronic obstructive pulmonary disease patients with concurrent presence of comorbid depression and anxiety. , 2022, Respiratory medicine.

[2]  S. Schofield,et al.  Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis and COPD , 2021, Chest.

[3]  Y. Erdoğan,et al.  EVALUATION OF ANXIETY AND DEPRESSION IN IDIOPATHIC PULMONARY FIBROSIS , 2020, Middle Black Sea Journal of Health Science.

[4]  S. Kon,et al.  Anxiety and depression in bronchiectasis: Response to pulmonary rehabilitation and minimal clinically important difference of the Hospital Anxiety and Depression Scale , 2020, Chronic respiratory disease.

[5]  A. Prasse,et al.  Short-Term Effects of Comprehensive Pulmonary Rehabilitation and its Maintenance in Patients with Idiopathic Pulmonary Fibrosis: A Randomized Controlled Trial , 2020, Journal of clinical medicine.

[6]  N. Koulouris,et al.  Impact of Depression on Patients With Idiopathic Pulmonary Fibrosis , 2020, Frontiers in Medicine.

[7]  K. Janssen,et al.  The impact of palliative care on quality of life, anxiety, and depression in idiopathic pulmonary fibrosis: a randomized controlled pilot study , 2020, Respiratory research.

[8]  J. Reed,et al.  Establishing the Minimal Clinically Important Difference for the Hospital Anxiety and Depression Scale in Patients With Cardiovascular Disease , 2019, Journal of cardiopulmonary rehabilitation and prevention.

[9]  F. Demirci,et al.  Are Idiopathic Pulmonary Fibrosis Patients more Anxious and Depressive than Patient’s with Other Interstitial Lung Disease? , 2019, Turkish Thoracic Journal.

[10]  S. Birring,et al.  King's Brief Interstitial Lung Disease questionnaire: responsiveness and minimum clinically important difference , 2019, European Respiratory Journal.

[11]  S. Han,et al.  Longitudinal Comparison of Anxiety and Depression Between Idiopathic Pulmonary Fibrosis (IPF) and Non-IPF Interstitial Lung Disease: A Prospective Cohort Study , 2019, B46. IDIOPATHIC INTERSTITIAL PNEUMONIA: NATURAL HISTORY.

[12]  N. T. Andersen,et al.  A web-based platform to accommodate symptoms of anxiety and depression by featuring social interaction and animated information in patients undergoing lumbar spine fusion: a randomized clinical trial. , 2019, The spine journal : official journal of the North American Spine Society.

[13]  E. Yalnız,et al.  Does the severity of interstitial lung disease affect the gains from pulmonary rehabilitation? , 2018, The clinical respiratory journal.

[14]  Jong Sun Park,et al.  Clinical impact of depression and anxiety in patients with idiopathic pulmonary fibrosis , 2017, PloS one.

[15]  P. Cullinan,et al.  Validity, responsiveness and minimum clinically important difference of the incremental shuttle walk in idiopathic pulmonary fibrosis: a prospective study , 2017, Thorax.

[16]  C. Ryerson,et al.  Determinants and outcomes of prolonged anxiety and depression in idiopathic pulmonary fibrosis , 2017, European Respiratory Journal.

[17]  W. Cooper,et al.  Health‐related quality of life in idiopathic pulmonary fibrosis: Data from the Australian IPF Registry , 2017, Respirology.

[18]  M. Ando,et al.  Depression Is Significantly Associated with the Health Status in Patients with Idiopathic Pulmonary Fibrosis , 2017, Internal medicine.

[19]  A. Holland,et al.  The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial , 2017, Thorax.

[20]  D. Needham,et al.  Distribution-based estimates of minimal important difference for hospital anxiety and depression scale and impact of event scale-revised in survivors of acute respiratory failure. , 2016, General hospital psychiatry.

[21]  N. Kaminski,et al.  Palliative care and location of death in decedents with idiopathic pulmonary fibrosis. , 2015, Chest.

[22]  J. Fiore,et al.  Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease , 2014, Respirology.

[23]  R. Abouqal,et al.  Responsiveness of the EuroQol EQ-5D and Hospital Anxiety and Depression Scale (HADS) in rheumatoid arthritis patients receiving tocilizumab , 2014, Clinical Rheumatology.

[24]  S. Kon,et al.  Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. , 2014, The Lancet. Respiratory medicine.

[25]  S. Kon,et al.  The Clinical COPD Questionnaire: response to pulmonary rehabilitation and minimal clinically important difference , 2013, Thorax.

[26]  Robin P. Smith,et al.  Depression in patients with idiopathic pulmonary fibrosis , 2013, Chronic respiratory disease.

[27]  C. Fell Idiopathic pulmonary fibrosis: phenotypes and comorbidities. , 2012, Clinics in chest medicine.

[28]  S. D'Amore,et al.  [Hospital anxiety and depression]. , 2011, Reumatismo.

[29]  B. Make,et al.  Benefits of Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis , 2011, Respiratory Care.

[30]  N. Kaminski,et al.  Impact of a disease-management program on symptom burden and health-related quality of life in patients with idiopathic pulmonary fibrosis and their care partners. , 2010, Heart & lung : the journal of critical care.

[31]  H. Collard,et al.  Pulmonary rehabilitation for interstitial lung disease. , 2010, Chest.

[32]  H. Schünemann,et al.  The minimal important difference of the hospital anxiety and depression scale in patients with chronic obstructive pulmonary disease , 2008, Health and quality of life outcomes.

[33]  R. Hays,et al.  Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. , 2008, Journal of clinical epidemiology.

[34]  Sally J. Singh,et al.  Development of a self-reported Chronic Respiratory Questionnaire (CRQ-SR) , 2001, Thorax.

[35]  P. Jones,et al.  Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease , 1999, Thorax.

[36]  G. Guyatt,et al.  Measurement of health status. Ascertaining the minimal clinically important difference. , 1989, Controlled clinical trials.

[37]  Huston Gj,et al.  The Hospital Anxiety and Depression Scale. , 1987, The Journal of rheumatology.

[38]  E. Wouters,et al.  Responsiveness and MCID Estimates for CAT, CCQ, and HADS in Patients With COPD Undergoing Pulmonary Rehabilitation: A Prospective Analysis. , 2017, Journal of the American Medical Directors Association.

[39]  S. Nathan,et al.  Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. , 2017, The Lancet. Respiratory medicine.